Jul 9, 2020 | News
(Missoula, MT) Inimmune, www.inimmune.com, a biotechnology company developing immune therapies and components for more effective vaccines, announced today that it raised $22 million in Series A funding. It was the Missoula-based company’s first outside...
Jul 9, 2020 | News
Inimmune lands the an $22 million dollar investment, let by Two Bear Capital. The investment is believed to be largest Series A funding in state history; Inimmune, which is based in Missoula, Montana, specializes in adjuvants for vaccines and has been developing a...
Jul 1, 2020 | News
Inimmune Corporation, a biotechnology company located in Missoula, MT, was recently awarded a $2 M grant from the National Institute for Allergy and Infectious Diseases (NIAID) under its Small Business Innovation Research (SBIR) Direct to Phase II program to advance a...
Jun 8, 2020 | News
Inimmune Corporation is joining in on efforts to develop a COVID-19 vaccine with a nasal spray that could offer protection against coronavirus. The research efforts are in collaboration with the University of Montana’s Center for Translational Medicine and Rocky...
Jun 7, 2020 | News
The science behind the silent killer. Here is how Inimmune is developing vaccines to help solve the opioid epidemic. Read full article: Science and the Silent Killer
Jun 7, 2020 | News
Bioscience research and development can unlock the economic potential of the Mountain West, providing jobs and substantial economic benefit. Read how Inimmune Corporation in Missoula, Montana is bridging academic research and commercial development with the...
